|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Departments of Pediatrics and
Biological Chemistry, Howard Hughes Medical Institute,
University of Michigan Medical Center, Ann Arbor, MI; Holland
Laboratory, American Red Cross, Rockville, MD; and Haemostasis
Research Group, MRC Clinical Sciences Centre, Imperial College School
of Medicine, London, United Kingdom.
Thrombin-activated factor VIII (FVIIIa) is a heterotrimer with the
A2 subunit (amino acid residues 373-740) in a weak ionic interaction
with the A1 and A3-C1-C2 subunits. Dissociation of the A2 subunit
correlates with inactivation of FVIIIa. Patients with hemophilia A have
been described whose plasmas display a discrepancy between their FVIII
activities, where the 1-stage activity assay displays greater activity
than the 2-stage activity assay. The molecular basis for one of these
mutations, ARG531HIS, is an increased
rate of A2 subunit dissociation. Examination of a homology model of the
A domains of FVIII predicted ARG531 to lie at the interface
of the A1 and A2 subunits and stabilize their interaction. Indeed,
patients with mutations either directly contacting ARG531
(ALA284GLU, ALA284PRO)
or closely adjacent to the A1-A2 interface in the tightly packed hydrophobic core (SER289LEU) have the same
phenotype of 1-stage/2-stage discrepancy. The ALA284GLU and
SER289LEU mutations in FVIII were produced by
transfection of COS-1 monkey cells. Compared to FVIII wild-type both
mutants had reduced specific activity by 1-stage clotting activity and
at least a 2-fold lower activity by 2-stage analysis (COAMATIC),
similar to the reported clinical data. Analysis of immunoaffinity
purified ALA284GLU and
SER289LEU proteins in an optical biosensor
demonstrated that A2 dissociation was 3-fold faster for both FVIIIa
mutants compared to FVIIIa wild-type. Therefore, these mutations within
the A1 subunit of FVIIIa introduce a similar destabilization of the
FVIIIa heterotrimer compared to the ARG531HIS
mutation within the A2 subunit and support that these residues stabilize the A domain interface of FVIIIa.
(Blood. 2001;97:685-691) Effective hemostasis is mediated by the regulated
and sequential activation of serine proteases in the coagulation
cascade. Factor VIII (FVIII) functions in the intrinsic pathway of
blood coagulation as a cofactor to accelerate by 100 000-fold the
activation of factor X by factor IXa that occurs on a phospholipid
surface in the presence of calcium ions.1 A quantitative
or qualitative deficiency of FVIII leads to the phenotype of the
bleeding disorder hemophilia A. The FVIII amino acid sequence, deduced
from the cloned complementary DNA (cDNA), identified that the molecule is synthesized as a single-chain polypeptide having the domain structure A1-A2-B-A3-C1-C2.2,3 On secretion from the cell, FVIII is processed to a heterodimer consisting of a carboxy
terminal-derived light chain (LC) of 80 kd in a metal ion-dependent
association with a variably proteolyzed (90-200 kd) amino
terminal-derived heavy chain (HC) fragment. The FVIII A domains share
almost 40% amino acid identity with each other and to the factor V
(FV) A domains, as well as with the A domains in the copper-binding
protein ceruloplasmin,4 suggesting the A domains may be
involved in copper ion binding. Indeed, studies have detected 1 mole
copper ion per mole of both FV and FVIII protein.5-7
In vivo, FVIII activity is regulated by proteolytic activation. On
thrombin cleavage of FVIII there is a rapid 50-fold increase and
subsequent first-order decay of procoagulant activity. The activation
coincides with proteolysis of both the HC and LC of FVIII.8 Thrombin activates FVIII through proteolytic
cleavage after ARG740, ARG1689, and
ARG372 generating an FVIIIa heterotrimer consisting of the
A1 subunit (50 kd) in a copper ion-dependent association with the
thrombin-cleaved LC (73 kd) and a free A2 subunit associated with the
A1 subunit through a weak ionic interaction. The FVIIIa heterotrimer
exhibits a pH-dependent dissociation of the A2 subunit from the
A1/A3-C1-C2 heterodimer that correlates with loss of procoagulant
activity.9-11 Porcine FVIIIa exhibits an increased
affinity for its A2 subunit compared to human FVIIIa and accordingly
demonstrates an increased specific activity.10,12 In
addition, a novel genetically engineered FVIII molecule, in which the
A2 subunit remains covalently linked to the LC even after thrombin
activation, has increased specific activity in vitro and abrogates the
first-order decay of procoagulant activity as observed for native
FVIII.13 These observations highlight the role of A2
dissociation in limiting FVIIIa activity in vitro. However, it is not
yet known whether spontaneous A2 subunit dissociation or further
proteolysis limits FVIIIa procoagulant activity in vivo.
Insight into this question has been gained by the recent
characterization of an unusual clinical phenotype of hemophilia A.
Patients with hemophilia A have been described whose plasmas display a
discrepancy between their FVIII activities, where the 1-stage (1-st)
activity assay displays greater activity than the 2-stage (2-st)
activity assay.14-18 Initially, the molecular mechanism for one of these mutations, a missense mutation,
ARG531HIS, was characterized to result from
increased rate of inactivation of FVIIIa by increased rate of A2
subunit dissociation.19 On thrombin activation, the
ARG531HIS A2 subunit exhibited a 4-fold
increased rate of dissociation from the A1/A3-C1-C2 heterodimer. The
increased instability of the ARG531HIS
heterotrimer would reduce its specific activity in both 1-st and 2-st
assays. However, the specific activity of
ARG531HIS is disproportionately reduced in the
2-step procedure, possibly due to the incubation phase in the first
step. This hemophilia A phenotype therefore supports previous in
vitro studies that have suggested that nonproteolytic regulation
of FVIIIa activity, via spontaneous A2 subunit dissociation, is
important in vivo.
Examination of a homology model of the A domains of
FVIII20 identified ARG531 to lie at the
interface of the A1 and A2 subunits. We hypothesize that the ARG to HIS
amino acid substitution destabilizes protein-protein interactions
between the A1 and A2 subunits. We also hypothesize that if this region
is important for FVIIIa stability, other mutations within this region
would have similar phenotypes. Interestingly, there are 3 described
hemophilia A mutations either directly contacting ARG531
(ALA284GLU, ALA284PRO)
or closely adjacent to ARG531HIS at the A
domain interface in the tightly packed hydrophobic core (SER289LEU). All patients with these mutations
have the phenotype of 1-st/2-st discrepancy. FVIII cDNA constructs were
prepared containing either the ALA284GLU or
SER289LEU mutations and the proteins were
expressed and purified from transfected COS-1 monkey cells. FVIII
harboring these missense mutations were secreted at similar levels to
FVIII wild-type (WT), had reduced specific activity by 1-st clotting
activity, and at least a 2-fold lower activity by 2-st analysis
(COAMATIC), similar to the reported clinical data. Analysis in an
optical biosensor demonstrated that on thrombin cleavage, A2
dissociation was 3-fold faster for both SER289LEU and ALA284GLU
compared to FVIII WT. Thus, these mutations within the A1 subunit of
FVIIIa demonstrate a similar destabilization of the A domain interface
as the originally characterized ARG531HIS
mutation within the A2 subunit. These results support a role for this
region in stabilizing the A domain interface of FVIIIa and support the
validity of the molecular model of the A domains. The amino acid
residues 281 to 290 within human FVIII are conserved in porcine,
canine, and murine FVIII. Further characterization of the key
protein-protein interactions within this region will advance genetic
engineering strategies aimed at improving the stability of the FVIIIa heterotrimer.
Materials
Plasmid mutagenesis
DNA transfection and analysis Plasmid DNA was transfected into COS-1 cells by the diethylaminoethyl-dextran method as previously described.22 Conditioned medium was harvested at 64 hours after transfection in the presence of 10% fetal bovine serum.Protein purification Purified ALA284GLU, SER289LEU, BDD-FVIII, and BDD-SER289LEU proteins were obtained from 200 mL conditioned medium from transiently transfected COS-1 cells by immunoaffinity chromatography23 yielding 750 to1500 ng per purification. FVIII WT protein was purified in parallel from stably transfected Chinese hamster ovary cells. The proteins eluted into the ethylene glycol-containing buffer were dialyzed and concentrated against a polyethylene glycol (molecular weight, ~15 000-20 000)-containing buffer24 and stored at 70°C.
FVIII activity and antigen assay FVIII activity was measured by (1) a 1-st aPTT clotting assay on an MLA Electra 750 fibrinometer (Medical Laboratory Automation, Pleasantville, NY) by reconstitution of human FVIII-deficient plasma or (2) a modified 2-st assay using the COAMATIC chromogenic assay according to the manufacturer's instructions. FVIII antigen was quantified by an anti-FVIII LC sandwich enzyme-linked immunosorbent assay (ELISA) method using the IMUBIND commercial kit according to the manufacturer's instructions (American Diagnostica).Kinetic measurements using biosensor technology The kinetics of the A2 subunit dissociation from thrombin-activated FVIII WT and mutant proteins were studied by surface plasmon resonance using the Biacore biosensor (Piscataway, NJ), which measures protein binding and subsequent dissociation in real time.25 Binding of 1 ng protein/mm2 of the biosensor chip produces a resonance signal of 200 Arc seconds. Monoclonal antibody ESH8 (50 µg/mL) in 10 mM sodium acetate, pH 5.0, was covalently coupled at 16.5 ng/mm2 to the activated carboxymethyldextran-coated biosensor cuvette via amino groups using succinimide ester chemistry.25 The carboxymethyldextran chip and reagents for its activation, N-ethyl-N'-(dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide, and deactivation, ethanolamine, were purchased from Affinity Sensors (Cambridge, United Kingdom). FVIII WT and mutant protein binding to ESH8 and their dissociation from the antibody and activation by thrombin were measured in 200 µL 20 mM Hepes, 0.15 NaCl, 5 mM CaCl2, 0.01% Tween 20, pH 7.4. The chip was regenerated by addition of 0.1 M glycine, pH 3.0, for 3 minutes, resulting in complete dissociation of FVIII proteins from the capture ESH8. Identical signals for reference binding of the FVIII proteins to immobilized ESH8 were obtained before and after regeneration.The values of the rate constants for dissociation (koff) of
FVIII WT or mutant proteins from immobilized ESH8 and those for dissociation of the A2 subunits on thrombin activation of immobilized FVIII proteins were calculated using the dissociation model with offset
described by the following equation:
R = Ri × exp(
Recombinant-derived ARG531HIS, ALA284GLU, and SER289LEU proteins demonstrate a similar functional phenotype to patient plasma FVIII The synthesis and secretion of FVIII WT and ARG531HIS, ALA284GLU, and SER289LEU mutants were compared after transient DNA transfection into COS-1 monkey cells. FVIII antigen determinations by ELISA were performed on conditioned media collected from 24 to 64 hours after transfection and were similar for all mutants compared to FVIII WT suggesting no significant defect in synthesis or secretion.FVIII activity (Figure 1) was measured by
a 1-st aPTT clotting assay or by a modified 2-st method using the
COAMATIC chromogenic assay. Activities were normalized to their
expressed FVIII antigen levels as determined by ELISA and are presented
as a percent of FVIII WT activity. Similar to the patient phenotypes
and data reported previously, ARG531HIS had
discrepant activity as measured by the 1-st aPTT clotting assay
(44% ± 15% of FVIII WT) compared to the 2-st chromogenic assay
(COAMATIC; 19% ± 4% of FVIII WT). For the
ALA284GLU mutation, 1-st aPTT (26% ± 6%)
and 2-st chromogenic assay (6% ± 4%) activities showed
discrepancy. For the SER289LEUmutation, 1-st
aPTT (32% ± 11%) and 2-st chromogenic assay (13% ± 5%)
activities also showed discrepancy. The activity measurements for the
patient plasmas represent all of the reported data obtained from the
HAMSTeRS hemophilia A mutation database.27 The slightly higher 2-st activity results obtained with the recombinant-derived mutant proteins are consistent with those obtained from the few reported patient plasmas where a chromogenic assay rather than the
classical 2-st assay was used.18 Following immunoaffinity purification of FVIII WT and mutant proteins from the conditioned medium, similar discrepancy in 1-st/2-st activities were obtained (data
not shown).
ARG531HIS, ALA284GLU, and SER289LEU proteins exhibit increased rate of A2 subunit dissociation from the thrombin-activated heterotrimer The relative rates of A2 dissociation for plasma-derived (pd) FVIII, FVIII WT, and mutant proteins were determined using an optical biosensor (Figure 2). An anti-LC antibody, ESH8, was covalently immobilized on a carboxymethyldextran-coated biosensor chip. Similar amounts (1.12 ng/mm2) of immunoaffinity purified FVIII WT or mutant proteins were bound to ESH8 antibody. Unbound material was removed by washing with buffer and free (nonproteolytic) dissociation from antibody was measured. The values of dissociation rate constants, koff = 8.9 ± 0.23 × 10 5/s, were
similar for FVIII WT and mutant proteins. Subsequently, thrombin was
added to a final concentration of 1 U/mL. Because the FVIII
preparations are bound to an ESH8-coated chip via the C2 domain of
their LCs, this interaction is not disturbed by thrombin cleavage and
the A1 subunit remains associated with the LC through the copper
ion-dependent linkage between the A1 and A3 domains. Thus, the
thrombin-induced release of the A2 subunit from the heterotrimer can be
measured as a dissociation curve registered by the optical biosensor.
Control experiments with thrombin concentrations ranging from 0.05 to
2.25 U/mL demonstrated that maximal thrombin cleavage under these
experimental conditions occurs at a thrombin concentration of 0.75 U/mL
(data not shown). The koff values and half-lives of A2
dissociation for the A2 subunits are presented in Table
1. Results for
ARG531HIS have been reported
previously19 and are presented for comparison purposes.
Both the ALA284GLU and
SER289LEU mutants displayed a 3-fold greater
rate of A2 dissociation compared to pdFVIII WT. Because A2 dissociation
correlates with inactivation, the mutant thrombin-activated
heterotrimers would be expected to inactivate approximately 3-fold
faster compared to plasma-derived FVIII or FVIII WT. The single
exponential model used by us to describe dissociation of the A2 subunit
observed for FVIII WT in this study is similar to that previously
reported for FVIIIa decay.12,24 The minor difference in
thrombin-mediated A2 dissociation rates for pdFVIII compared to
recombinant FVIII WT did not reach statistical significance
(P = .24, n = 5).
Because these mutations were expressed within the FVIII WT construct, they contain a B domain. The B domain is also released on thrombin activation and contributes to the loss of mass observed by the optical biosensor. Although the release of B-domain fragment(s) is immediate on thrombin activation we prepared BDD forms of FVIII and the SER289LEU mutant so that only A2 subunit dissociation would be measured by the optical biosensor. Both BDD-FVIII and BDD-SER289LEU were expressed from COS cells by transient transfection and the purified proteins subjected to the same analysis as the full-length proteins. BDD-SER289LEU exhibited similar 1-st/2-st discrepancy as SER289LEU in activity assays (data not shown). Purified BDD-SER289LEU was then subjected to optical biosensor analysis and displayed 5-fold greater rate of A2 dissociation compared to the BDD-FVIII control. Because the amount of each immobilized FVIII was approximately 310 RU when thrombin was added, the reduction of the resonance signal on dissociation of A2 is 28% and 27.6% for BDD-FVIII and BDD-SER289LEU, respectively. This is identical to the expected reduction of the resonance signal (27.6%) on complete dissociation of the A2 subunit calculated using molecular weights of 170 kd and 123 kd for BDD-FVIII and its A1/A3-C1-C2 dimer. In contrast, B domain-containing samples in panels A and B of Figure 2 demonstrated an initial rapid loss of resonance signal immediately following addition of thrombin (consistent with loss of B-domain fragments) that was not observed for the BDD samples in panel C. However, all samples subsequently exhibited a relatively slower loss of resonance signal (consistent with A2 subunit dissociation) that was used to calculate the koff for dissociation. ARG531HIS, ALA284GLU, and SER289LEU proteins exhibit unstable activity during the first phase of the 2-st chromogenic assay To address the effect of the increased rate of A2 dissociation on the discrepant activity of the mutants in the 2-st assay, FVIII WT, ARG531HIS, ALA284GLU, and SER289LEU proteins were assayed in the chromogenic assay under conditions of increased duration of the first stage (Figure 3). Conditioned media samples collected at 64 hours following transfection were used for the assay. Antigen concentrations were similar for FVIII WT and the mutants and ranged between 10 and 20 ng/mL. The manufacturer's protocol was modified whereby duplicated samples were incubated in the first stage for 2, 4, 8, and 16 minutes in parallel with FVIII WT. The first stage was initiated for the 16-minute samples first, followed by the 8-, 4-, and 2-minute incubation samples. The second stage was then initiated for all samples simultaneously and then measured together. During the first-stage incubation, the FVIII samples are activated due to the presence of thrombin in the reagent mix. The resultant FVIIIa is then available to exert cofactor activity with factor IXa to generate factor Xa from unactivated factor X. The total amount of factor Xa generated in the first stage is then quantified at the second stage by the amount of chromophore released from the chromogenic reagent by factor Xa. A standard curve was performed in parallel with dilutions of pooled normal plasma and incubated for 2 minutes during the first stage. The y-axis of Figure 3 is thus the relative FVIII activity of the samples following the various one-stage incubations as compared to this standard curve. We hypothesized that both FVIII WT and the mutants with increased rate of A2 dissociation would become fully activated in the first-stage incubation and exhibit FVIII activity as determined by the total amount of factor Xa generated. However, with increased rate of inactivation due to A2 dissociation, the mutants would be unable to sustain FVIII activity and the total amount of factor Xa generated would not increase at the same rate as FVIII WT. Indeed, FVIII WT was observed to have continued cofactor activity (as demonstrated by increasing factor Xa generation) throughout even the longest first-stage incubation of 16 minutes. In contrast, each of the mutants, though showing continued cofactor activity for up to 4 minutes of first-stage incubation fail to contribute to any further factor Xa generation beyond 4 minutes. This is consistent with complete spontaneous inactivation of the mutants after 4 minutes. Thus the relative amount of factor Xa generation decreases with increasing duration of first-stage incubation compared to FVIII WT.
Despite the 4 decades of availability of both the 1-st and 2-st assays for measuring FVIII activity, there is still no consensus on which method most accurately represents FVIII cofactor function in vivo. Although there is little assay discrepancy between the methods when comparing human plasmas or various FVIII-containing concentrates, considerable variability has been described when not comparing FVIII molecules with similar molecular composition and structure. For instance, recombinant FVIII shows a reduced potency in the 1-st assay compared to the 2-st assay (chromogenic) when plasma FVIII is used as the standard.28 Similar discrepancy is observed following infusion of recombinant FVIII into patients with hemophilia, prompting recommendations that recombinant FVIII be used to prepare the standards for this type of analysis. In addition, a naturally occurring patient mutation was described whereby the 1-st assay reports reduced activity compared to the 2-st assay.29 The mutation GLU720LYS within FVIII results in a mild hemophilia A phenotype with detectable circulating FVIII antigen. Patients with this mutation exhibit normal levels of FVIII cofactor activity as measured by the chromogenic assay method but have reduced levels of procoagulant activity when measured by 1-st assay. Recombinant GLU720LYS was purified and found to require higher concentrations of FIXa for full cofactor activity as measured by FXa generation, whereas lower concentrations of FIXa (as would be expected in a 1-st assay) resulted in 2- to 3-fold reduced activity. It was proposed that this mutation at residue 720, adjacent to one of 3 putative FIXa binding sites within the A2 domain (residues 698-712), could result in reduced affinity for FIXa and therefore contribute to the higher FIXa concentration required for optimal cofactor activity. The 1-st/2-st discrepancy described above relates to reduced FVIII activity in the 1-st compared to the 2-st assay. However, the hemophilia A phenotype analyzed in this report relates to FVIII activity that is reduced in the 2-st assay compared to the 1-st assay. Early reports characterizing this clinical phenotype were attributed to type 2N von Willebrand disease (vWD) where a mutation in the FVIII binding site within von Willebrand factor leads to reduced affinity for FVIII in plasma.30,31 The reduced FVIII activity in the 2-st assay was due to increased adsorption of FVIII to Al(OH)3 during the pretreatment phase of the 2-st assay. This has been subsequently confirmed in an additional recent report of type 2N vWD.32 This type of 1-st/2-st activity discrepancy was first characterized in hemophilia A pedigrees in 198333 suggesting it was related to specific FVIII mutations. Subsequently, several specific mutations were described.18 Biochemical analysis of a recombinant-derived form of one of these mutations, ARG531HIS, led to the observation that the thrombin-activated mutant protein had an increased rate of spontaneous inactivation secondary to an increased rate of A2 subunit dissociation.19 This suggested a role for this particular residue in contributing to the stabilization of the FVIIIa heterotrimer. An additional report describes analysis of patient plasma from a hemophilia A patient with the ARG531HIS mutation.34 Using a FVIII ELISA specific for heterodimeric FVIII, this patient had reduced amounts of heterodimeric FVIII, suggesting the mutation may also reduce the stability of the triplicated A domains even before thrombin activation, further highlighting the role of protein-protein interactions within the A-domain interface. Molecular modeling of the environment of the ARG531
residue, using the homology-derived FVIII A domain model20
predicted that the ARG531 arginine side chain in A2
participates in an H-bond with the main chain carbonyl oxygen of
ARG282 in A1, providing both a plausible explanation for
the molecular pathology of the hemophilic FVIII variant and support for
the accuracy of the model. However, the model also permitted
predictions concerning the hemophilic variants
ALA284PRO and
ALA284GLU, which also show the 1-st/2-st
discrepancy18,35: here the small hydrophobic side chain of
ALA284 packs closely against the ARG531 side
chain at the A1-A2 boundary, very close to the
ARG531-ARG282 H-bond (Figure
4A). Replacement of the small alanine
side chain with that of either proline or glutamic acid (as in the hemophilic FVIII variants) may be predicted to disrupt the stabilizing ARG531-ARG282 H-bond. We have tested this
prediction by expression and characterization of the
ALA284GLU variant.
In addition we have expressed and studied SER289LEU, another hemophilia mutation in A1 with a similar 1-st/2-st discrepancy, placed close in the model to the A1-A2 domain interface. In this case, inspection of the FVIII A domain model predicts an interdomain H-bond between the A1 and A3 domains, between the side chains of SER289 and TYR1979 (Figure 4B). Replacement by the bulky leucine side chain is predicted to abolish this interdomain H-bond but also to disrupt packing very close to the interface between all 3 A domains at the pseudo-threefold axis of the model. Our in vitro characterization of both of these FVIII missense mutations located within the A1 subunit (at residues 284 and 289) confirms the hemophilia A clinical phenotype of 1-st/2-st discrepancy and demonstrates the same molecular phenotype of increased rate of A2 subunit dissociation on thrombin cleavage. These observations provide evidence that the packing of the triplicated A domains is critical to FVIII function and that interdomain protein-protein interactions are required for stabilizing both the unactivated and activated forms of the molecule. These observations also provide first experimental evidence that validates the molecular model of the triplicated A domains based on their homology to ceruloplasmin. The insights gained from studying this patient phenotype and the molecular characterization of these particular mutations has extended the observations made from analyzing the ARG531HIS mutation. Two additional reports have added to our observations. A family pedigree has been described in which all members have 2-st FVIII activities that are one half of that measured by 1-st assay.36 This pedigree included affected males as well as homozygous females. Molecular analysis identified a missense mutation at residue 694 within the A2 subunit where ILE is substituted for ASN. This mutation predicts loss of intradomain hydrogen bonds as well as introduces severe side-chain packing constraints within an area adjacent to the A2-A3 interface. The second report describes a hemophilia A patient with the same 1-st/2-st discrepancy phenotype attributed to a missense mutation at residue 1954 within the A3 subunit where LEU is substituted for a HIS.37 This patient's 1-st activity assay was within normal limits though the 2-st activity assay and chromogenic assay were only 18% and 35% of normal, respectively. This residue is in close proximity to TYR1979, and to residues ARG698 and MET1947, both previously indicated to lie at the A2-A3 interface and associated with the same 1-st/2-st discrepant mild hemophilia phenotype under discussion.18,35 This report is particularly interesting in that the hemophilia phenotype was more accurately reflected by the 2-st assay rather than the more widely used 1-st assay. Thus, mild hemophilia A variants can be missed when screened in laboratories that exclusively use the 1-st aPTT-based activity assay. These observations, as well as those reported here, showing that the 2-st assay more closely reflects in vivo FVIII clotting activity, support that FVIII activity is limited by A2 dissociation in vivo. There are reports of this particular discrepant hemophilia phenotype
associated with predictions of disrupted interactions at or close to
the A1-A2, A1-A3, and A2-A3 domain interfaces. Figure
5 shows a global view of the FVIII A
domain model viewed down the pseudo-threefold axis, showing the
predicted positions of the amino acids mentioned above, which are
associated with the 1-st/2-st discrepancy in hemophilic subjects. There
is a clear clustering of all these residues at or very close to the
interface of the A2 domain with the A1 and A3 domains.
The proposed pseudo-threefold axis at the hydrophobic core of the A1-A2-A3 interface is tightly packed and predicts several interdomain interactions. These lie at the interface of A1-A2, A2-A3, and A1-A3. Sufficient disruption of these protein-protein interactions along the pseudo-threefold axis would lead to destabilization and increased propensity for dissociation particularly after thrombin cleavage whereby covalent bonds flanking the A2 subunit are lost. The validation of the molecular modeling of the A domains and the characterization of these putative interdomain protein-protein interactions now allows the hypothesis that increased stabilization of this interface would lead to greater stability of FVIII and increased cofactor activity. There is now opportunity to explore complementary mutations that might allow better packing and stabilization of the A domains to test this hypothesis. Novel bioengineering strategies may ultimately enable strategic interdomain cross-linking to provide further stabilization of FVIIIa. Further characterization of FVIIIa-FIXa sites of interaction combined with both molecular modeling and crystallography observations may ultimately allow the design of a peptidomimetic for FVIIIa.
Submitted April 17, 2000; accepted October 6, 2000.
Supported by National Institutes of Health grant HL52173 and by NIHCHD HD28820. S.W.P. and E.L.S. are Faculty Scholars of the American Society of Hematology.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Randal J. Kaufman, Howard Hughes Medical Institute, University of Michigan Medical Center, Ann Arbor, MI 48109; e-mail: kaufmanr{at}umich.edu.
1.
van Dieijen G, Tans G, Rosing J, Hemker HC.
The role of phospholipid and factor VIIIa in the activation of bovine factor X.
J Biol Chem.
1981;256:3433-3442 2. Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984;312:337-342[CrossRef][Medline] [Order article via Infotrieve]. 3. Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature. 1984;312:342-347[CrossRef][Medline] [Order article via Infotrieve].
4.
Koschinsky ML, Funk WD, van Oost BA, MacGillivray RT.
Complete cDNA sequence of human preceruloplasmin.
Proc Natl Acad Sci U S A.
1986;83:5086-5090 5. Bihoreau N, Pin S, de Kersabiec AM, Vidot F, Fontaine-Aupart MP. Copper-atom identification in the active and inactive forms of plasma-derived FVIII and recombinant FVIII-delta II. Eur J Biochem. 1994;222:41-48[Medline] [Order article via Infotrieve].
6.
Mann KG, Lawler CM, Vehar GA, Church WR.
Coagulation factor V contains copper ion.
J Biol Chem.
1984;259:12949-12951
7.
Tagliavacca L, Moon N, Dunham WR, Kaufman RJ.
Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII.
J Biol Chem.
1997;272:27428-27434 8. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry. 1986;25:505-512[CrossRef][Medline] [Order article via Infotrieve].
9.
Lollar P, Parker CG.
pH-dependent denaturation of thrombin-activated porcine factor VIII.
J Biol Chem.
1990;265:1688-1692
10.
Lollar P, Parker ET.
Structural basis for the decreased procoagulant activity of human factor VIII compared to the porcine homolog.
J Biol Chem.
1991;266:12481-12486
11.
Fay PJ, Smudzin TM.
Characterization of the interaction between the A2 subunit and A1/A3-C1-C2 dimer in human factor VIIIa.
J Biol Chem.
1992;267:13246-13250
12.
Lollar P, Parker ET, Fay PJ.
Coagulant properties of hybrid human/porcine factor VIII molecules.
J Biol Chem.
1992;267:23652-23657
13.
Pipe SW, Kaufman RJ.
Characterization of a genetically engineered inactivation-resistantcoagulation factor VIIIa.
Proc Natl Acad Sci U S A.
1997;94:11851-11856 14. Over J. Methodology of the one-stage assay of factor VIII (VIII:C). Scand J Haematol Suppl. 1984;41:13-24[Medline] [Order article via Infotrieve]. 15. Barrowcliffe TW. Comparisons of one-stage and two-stage assays of factor VIII:C. Scand J Haematol Suppl. 1984;41:39-54[Medline] [Order article via Infotrieve]. 16. Rosen S. Assay of factor VIII:C with a chromogenic substrate. Scand J Haematol Suppl. 1984;40:139-145[Medline] [Order article via Infotrieve]. 17. Duncan EM, Duncan BM, Tunbridge LJ, Lloyd JV. Familial discrepancy between the one-stage and two-stage factor VIII methods in a subgroup of patients with haemophilia A. Br J Haematol. 1994;87:846-848[Medline] [Order article via Infotrieve]. 18. Rudzki Z, Duncan EM, Casey GJ, Neumann M, Favaloro EJ, Lloyd JV. Mutations in a subgroup of patients with mild haemophilia A and a familial discrepancy between the one-stage and two-stage factor VIII:C methods. Br J Haematol. 1996;94:400-406[CrossRef][Medline] [Order article via Infotrieve].
19.
Pipe SW, Eickhorst AN, McKinley SH, Saenko EL, Kaufman RJ.
Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo.
Blood.
1999;93:176-183
20.
Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook G.
A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin.
Blood.
1997;89:2413-2421 21. Kaufman RJ. Vectors used for expression in mammalian cells. Methods Enzymol. 1990;185:487-511[Medline] [Order article via Infotrieve]. 22. Pittman DD, Kaufman RJ. Site-directed mutagenesis and expression of coagulation factors VIIIand V in mammalian cells. Methods Enzymol. 1993;222:236-260[Medline] [Order article via Infotrieve].
23.
Michnick DA, Pittman DD, Wise RJ, Kaufman RJ.
Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage.
J Biol Chem.
1994;269:20095-20102
24.
Fay PJ, Beattie TL, Regan LM, O'Brien LM, Kaufman RJ.
Model for the factor VIIIa-dependent decay of the intrinsic factor Xase: role of subunit dissociation and factor IXa-catalyzed proteolysis.
J Biol Chem.
1996;271:6027-6032 25. Johnsson B, Lofas S, Lindquist G. Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. Anal Biochem. 1991;198:268-277[CrossRef][Medline] [Order article via Infotrieve]. 26. O'Shannessy DJ, Brigham-Burke M, Soneson KK, Hensley P, Brooks I. Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of nonlinear least squares analysis methods. Anal Biochem. 1993;212:457-468[CrossRef][Medline] [Order article via Infotrieve].
27.
Kemball-Cook G, Tuddenham EGD, Wacey AI.
The factor VIII structure and mutation resource site: HAMSTeRS version 4.
Nucleic Acids Res.
1998;26:216-219 28. Barrowcliffe TW, Raut S, Hubbard AR. Discrepancies in potency assessment of recombinant FVIII concentrates. Haemophilia. 1998;4:634-640[CrossRef][Medline] [Order article via Infotrieve]. 29. Roelse JC, de Laaf RTM, Mertens K, van Mourik JA, Oldenburg J, Voorberg J. Altered sensitivity towards factor IXa explains assay discrepancies in plasma of haemophilia A patients with a GLU720 LYS substitution in factor VIII [abstract]. Thromb Haemost. 1999;82:5a.
30.
Montgomery RR, Hathaway WE, Johnson J, Jacobson L, Muntean W.
A variant of von Willebrand's disease with abnormal expression of factor VIII procoagulant activity.
Blood.
1982;60:201-207
31.
Kroner PA, Foster PA, Fahs SA, Montgomery RR.
The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.
Blood.
1996;87:1013-1021 32. Duncan EM, Rodgers SE, Lerda N, et al. Different underlying causes for the discrepancy between FVIII:C 1-stage and 2-stage results in type 2N vWD and variant mild haemophilia A [abstract]. Thromb Haemost. 1999;82:274a. 33. Hathaway WE, Christian MJ, Jacobson LJ. Variant mild haemophilia: discrepancy in one stage and two stage factor VIII assays [abstract]. Thromb Haemost. 1983;50:1123a. 34. Celie PH, Van Stempvoort G, Jorieux S, Mazurier C, Van Mourik JA, Mertens K. Substitution of Arg527 and Arg531 in factor VIII associated with mild haemophilia A: characterization in terms of subunit interaction and cofactor function. Br J Haematol. 1999;106:792-800[CrossRef][Medline] [Order article via Infotrieve]. 35. Mazurier C, Gaucher C, Jorieux S, Parquet-Gernez A. Mutations in the FVIII gene in seven families with mild haemophilia A [letter]. Br J Haematol. 1997;96:426-427[CrossRef][Medline] [Order article via Infotrieve]. 36. Schwaab R, Oldenburg J, Kemball-Cook G, et al. Assay discrepancy in mild haemophilia A due to a factor VIII missense mutation (Asn694Ile) in a large Danish family. Br J Haematol. 2000;109:523-528[CrossRef][Medline] [Order article via Infotrieve].
37.
Keeling DM, Sukhu K, Kemball-Cook G, Waseem N, Bagnall R, Lloyd JV.
Diagnostic importance of the two-stage factor VIII:C assay demonstrated by a case of mild haemophilia associated with His1954
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  H. Wakabayashi, F. Varfaj, J. DeAngelis, and P. J. Fay Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface Blood, October 1, 2008; 112(7): 2761 - 2769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wakabayashi and P. J. Fay Identification of Residues Contributing to A2 Domain-dependent Structural Stability in Factor VIII and Factor VIIIa J. Biol. Chem., April 25, 2008; 283(17): 11645 - 11651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Doering, J. F. Healey, E. T. Parker, R. T. Barrow, and P. Lollar High Level Expression of Recombinant Porcine Coagulation Factor VIII J. Biol. Chem., October 4, 2002; 277(41): 38345 - 38349. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
) and 2-stage (
) activity assays from plasmas
obtained from hemophilia A patients with these missense mutations as
reported in the hemophilia A mutation database. (B) Full-length cDNAs
containing missense mutations generated by oligonucleotide
site-directed mutagenesis were expressed in COS-1 monkey kidney cells.
The data from recombinant-derived protein was obtained from assaying
the activity in the conditioned medium at 64 hours following
transfection. One-stage activity (
;
SER289LEU, 
;
ALA284GLU, 
.
Leu substitution in the factor VIII A3 domain.
Br J Haematol.
1999;105:1123-1126